Product Pathways
BCP0017 AT9283
AT9283 is a potent pan-Aurora inhibitor for Aurora A, Aurora B, JAK3, JAK2 and Abl with IC50 of 3 nM, 3 nM, 1.1 nM, 1.2 nM and 4 nM, respectively.
BCP0263 BMS-2
A cell-permeable pyrrolopyridine-pyridone compound that acts as a potent ATP-competitive inhibitor of Met, Flt-3 and VEGFR2.
BCP0345 AP24534(Ponatinib)
AP24534 is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM, respectively.
BCP0540 AC220
AC220 is a uniquely potent and selective FLT3 inhibitor.
BCP000663 Sunitinib Malate
Sunitinib Malate (Sutent) is a multitargeted FLT3, PDGFRs, VEGFRs, and Kit kinase inhibitor with Ki of 0.009 and 0.008 M for Flk-1 and PDGFR, respectively.
BCP000705 SU14813
SU14813, a small molecule identified from the same chemical library used to isolate sunitinib, hasbroad-spectrum RTK inhibitory activity through binding to and inhibition of VEGFR, PDGFR, KIT, and FLT3.
BCP000844 TG101209/TG-101209
BCP000975 KW2449
KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation
BCP001300 Dovitinib lactate monohydrate
BCP001656 AST487
AST 487 displays high selectivity and potency toward FLT3 as a molecular target, and which could potentially be used to override drug resistance in AML.
第一页 1 2 最后页 
Only for research purpose , not for human consumption Copyright©2012 ShangHai Biochempartner Co.,Ltd.